<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117615">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818869</url>
  </required_header>
  <id_info>
    <org_study_id>D0542C00002</org_study_id>
    <nct_id>NCT01818869</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Administration of Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
      of multiple ascending doses of AZD8848 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate
      the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Administration of
      Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline up to 77 days in safety variables (adverse events, vital signs, body temperature, physical exams, ECGs, clinical laboratory tests, pulse oximetry, spirometry).</measure>
    <time_frame>From screening visit (Day -42) through the Treatment Follow Up visit (Day 35) at multiple timepoints up to 77  days.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose pharmacokinetics profile for AZD8848 and its acid metabolite (AZ12432045) combined and, if possible, for AZD8848 alone in plasma and urine from healthy subjects</measure>
    <time_frame>Plasma: From Days 1 and 22, pre-dose, 5, 10, 20, 30, 45, 60, 90 min, 2, 3, 4, 6, 8 and 24 hrs post dose. Urine: From days 1 and 22, pre-dose, 0 to 6, 6 to 12 and 12 to 24 hrs post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters: Cmax, tmax, area under the plasma concentration-time curve from zero to 24 hours postdose (AUC(0-24)), from zero to the time of the last quantifiable concentration (AUC(0-t)) and from zero to infinity (AUC), CL/F, Vz/F, CLR and Ae</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple dose pharmacokinetics profile for AZD8848 and its acid metabolite (AZ12432045) combined and, if possible, for AZD8848 alone in plasma</measure>
    <time_frame>Plasma: From Days 1 and 22, pre-dose, 5, 10, 20, 30, 45, 60, 90 min, 2, 3, 4, 6, 8 and 24 hrs post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters:  AUC accumulation ratio and Cmax accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect after multiple doses of inhaled AZD8848 by assessment of the CXCL10 biomarker concentration in plasma</measure>
    <time_frame>From Days 1 and 22, pre-dose, 24 and 48 hrs post dose. One sample 7 to 13 days post last dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacodynamic effect: CXCL10 concentration and change-from-baseline ratios in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Safety,</condition>
  <condition>Tolerability,</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AZD8848</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match AZD8848</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8848</intervention_name>
    <description>Multiple doses inhaled IMP via a nebulizer</description>
    <arm_group_label>AZD8848</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match AZD8848</intervention_name>
    <description>Multiple doses inhaled matching placebo via a nebulizer</description>
    <arm_group_label>Placebo to match AZD8848</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects aged 18 to 50  years (inclusive) with suitable
             veins for cannulation or repeated venipuncture

          -  Women must be of non-childbearing potential or must have been stable on a highly
             effective contraceptive for at least 3 months prior to Screening and be willing to
             continue on the chosen contraceptive with additonal use of condom until 3 months
             postdose

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the
             first day of investigational product administration until 3 months after the last
             administration of investigational product

          -  Have a body mass index (BMI) between 18 and 32 kg/m2 and weigh at least 50 kg and no
             more than 110 kg

          -  Women  must have a negative pregnancy test at screening and on admission to the study
             centre, must have a date of last menstruation, must not be lactating or must be of
             non-childbearing potential

        Exclusion Criteria:

          -  Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:
             SBP &gt;140 mmHg, Diastolic blood pressure (DBP) &gt;90 mmHg, Heart rate &lt;40 or &gt;85 beats
             per minute

          -  History of asthma or allergic rhinitis

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms or family history of long QT
             syndrome

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the Investigator or history of hypersensitivity to drugs with a similar
             chemical structure or class as AZD8848 - Any clinically significant abnormalities in
             clinical chemistry.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Mant, BSc, MB BS, MRCP, FRCP, FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital, 6 Newcomen Street London SE1 1YR UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aray Aggarwal</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Pharmaceuticals 35 Gathouse Drive, Waltham, Ma 02451 United States</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>Phase I,</keyword>
  <keyword>pharmacokinetic,</keyword>
  <keyword>pharmacodynamic,</keyword>
  <keyword>inhaled</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
